These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
188 related articles for article (PubMed ID: 29066893)
1. Application of multifunctional targeting epirubicin liposomes in the treatment of non-small-cell lung cancer. Song XL; Ju RJ; Xiao Y; Wang X; Liu S; Fu M; Liu JJ; Gu LY; Li XT; Cheng L Int J Nanomedicine; 2017; 12():7433-7451. PubMed ID: 29066893 [TBL] [Abstract][Full Text] [Related]
2. Development of R Liu JJ; Tang W; Fu M; Gong XQ; Kong L; Yao XM; Jing M; Cai FY; Li XT; Ju RJ Artif Cells Nanomed Biotechnol; 2019 Dec; 47(1):1947-1960. PubMed ID: 31079495 [TBL] [Abstract][Full Text] [Related]
3. RPV-modified epirubicin and dioscin co-delivery liposomes suppress non-small cell lung cancer growth by limiting nutrition supply. Kong L; Cai FY; Yao XM; Jing M; Fu M; Liu JJ; He SY; Zhang L; Liu XZ; Ju RJ; Li XT Cancer Sci; 2020 Feb; 111(2):621-636. PubMed ID: 31777993 [TBL] [Abstract][Full Text] [Related]
4. Liposomes, modified with PTD(HIV-1) peptide, containing epirubicin and celecoxib, to target vasculogenic mimicry channels in invasive breast cancer. Ju RJ; Li XT; Shi JF; Li XY; Sun MG; Zeng F; Zhou J; Liu L; Zhang CX; Zhao WY; Lu WL Biomaterials; 2014 Aug; 35(26):7610-21. PubMed ID: 24912818 [TBL] [Abstract][Full Text] [Related]
5. Enhanced antitumor efficacy using epirubicin and schisandrin B co-delivery liposomes modified with PFV via inhibiting tumor metastasis. Jing M; Bi XJ; Yao XM; Cai F; Liu JJ; Fu M; Kong L; Liu XZ; Zhang L; He SY; Jia LQ; Li XT Drug Dev Ind Pharm; 2020 Apr; 46(4):621-634. PubMed ID: 32162988 [TBL] [Abstract][Full Text] [Related]
6. Targeting Epirubicin Plus Quinacrine Liposomes Modified with DSPE-PEG2000-C(RGDfK) Conjugate for Eliminating Invasive Breast Cancer. Sun MG; Shi JF; Li XY; Zhao Y; Ju RJ; Mu LM; Yan Y; Li XT; Zeng F; Lu WL J Biomed Nanotechnol; 2015 Aug; 11(8):1339-53. PubMed ID: 26295137 [TBL] [Abstract][Full Text] [Related]
7. Destruction of vasculogenic mimicry channels by targeting epirubicin plus celecoxib liposomes in treatment of brain glioma. Ju RJ; Zeng F; Liu L; Mu LM; Xie HJ; Zhao Y; Yan Y; Wu JS; Hu YJ; Lu WL Int J Nanomedicine; 2016; 11():1131-46. PubMed ID: 27042063 [TBL] [Abstract][Full Text] [Related]
8. Inhibition of tumor metastasis by targeted daunorubicin and dioscin codelivery liposomes modified with PFV for the treatment of non-small-cell lung cancer. Wang Y; Fu M; Liu J; Yang Y; Yu Y; Li J; Pan W; Fan L; Li G; Li X; Wang X Int J Nanomedicine; 2019; 14():4071-4090. PubMed ID: 31239668 [No Abstract] [Full Text] [Related]
9. Antitumor efficacy of Lf modified daunorubicin plus honokiol liposomes in treatment of brain glioma. Liu S; Zhang SM; Ju RJ; Xiao Y; Wang X; Song XL; Gu LY; Cheng L; Li XT; Chen GR Eur J Pharm Sci; 2017 Aug; 106():185-197. PubMed ID: 28583810 [TBL] [Abstract][Full Text] [Related]
10. The efficacy of mitochondrial targeting antiresistant epirubicin liposomes in treating resistant leukemia in animals. Men Y; Wang XX; Li RJ; Zhang Y; Tian W; Yao HJ; Ju RJ; Ying X; Zhou J; Li N; Zhang L; Yu Y; Lu WL Int J Nanomedicine; 2011; 6():3125-37. PubMed ID: 22163164 [TBL] [Abstract][Full Text] [Related]
11. Functional paclitaxel plus honokiol micelles destroying tumour metastasis in treatment of non-small-cell lung cancer. Wang X; Cheng L; Xie HJ; Ju RJ; Xiao Y; Fu M; Liu JJ; Li XT Artif Cells Nanomed Biotechnol; 2018; 46(sup2):1154-1169. PubMed ID: 30043652 [TBL] [Abstract][Full Text] [Related]
12. The use of functional epirubicin liposomes to induce programmed death in refractory breast cancer. Liu L; Mu LM; Yan Y; Wu JS; Hu YJ; Bu YZ; Zhang JY; Liu R; Li XQ; Lu WL Int J Nanomedicine; 2017; 12():4163-4176. PubMed ID: 28615943 [TBL] [Abstract][Full Text] [Related]
13. Combination of TRAIL and actinomycin D liposomes enhances antitumor effect in non-small cell lung cancer. Guo L; Fan L; Ren J; Pang Z; Ren Y; Li J; Wen Z; Qian Y; Zhang L; Ma H; Jiang X Int J Nanomedicine; 2012; 7():1449-60. PubMed ID: 22619505 [TBL] [Abstract][Full Text] [Related]
14. A nanostructure of functional targeting epirubicin liposomes dually modified with aminophenyl glucose and cyclic pentapeptide used for brain glioblastoma treatment. Zhang CX; Zhao WY; Liu L; Ju RJ; Mu LM; Zhao Y; Zeng F; Xie HJ; Yan Y; Lu WL Oncotarget; 2015 Oct; 6(32):32681-700. PubMed ID: 26418720 [TBL] [Abstract][Full Text] [Related]
15. Targeted delivery of epirubicin to tumor-associated macrophages by sialic acid-cholesterol conjugate modified liposomes with improved antitumor activity. Zhou S; Zhang T; Peng B; Luo X; Liu X; Hu L; Liu Y; Di D; Song Y; Deng Y Int J Pharm; 2017 May; 523(1):203-216. PubMed ID: 28336455 [TBL] [Abstract][Full Text] [Related]
16. Tumor Microenvironmental Responsive Liposomes Simultaneously Encapsulating Biological and Chemotherapeutic Drugs for Enhancing Antitumor Efficacy of NSCLC. Kong L; Zhang SM; Chu JH; Liu XZ; Zhang L; He SY; Yang SM; Ju RJ; Li XT Int J Nanomedicine; 2020; 15():6451-6468. PubMed ID: 32922011 [TBL] [Abstract][Full Text] [Related]
17. Efficacy of epi-1 modified epirubicin and curcumin encapsulated liposomes targeting-EpCAM in the inhibition of epithelial ovarian cancer cells. Wang YJ; Tang L; Lu XH; Liu JT; Wang YY; Geng HX; Li XT; An Q J Liposome Res; 2023 Jun; 33(2):197-213. PubMed ID: 36440599 [TBL] [Abstract][Full Text] [Related]
18. BBB-penetrating codelivery liposomes treat brain metastasis of non-small cell lung cancer with EGFR Yin W; Zhao Y; Kang X; Zhao P; Fu X; Mo X; Wang Y; Huang Y Theranostics; 2020; 10(14):6122-6135. PubMed ID: 32483443 [TBL] [Abstract][Full Text] [Related]
19. FNC inhibits non-small cell lung cancer by activating the mitochondrial apoptosis pathway. Jing X; Niu S; Liang Y; Chen H; Wang N; Peng Y; Ma F; Yue W; Wang Q; Chang J; Zhang Y; Zhang Y Genes Genomics; 2022 Jan; 44(1):123-131. PubMed ID: 34697761 [TBL] [Abstract][Full Text] [Related]
20. Application of functional vincristine plus dasatinib liposomes to deletion of vasculogenic mimicry channels in triple-negative breast cancer. Zeng F; Ju RJ; Liu L; Xie HJ; Mu LM; Zhao Y; Yan Y; Hu YJ; Wu JS; Lu WL Oncotarget; 2015 Nov; 6(34):36625-42. PubMed ID: 26429872 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]